f. hoffmann-la roche ag

 

  • [58] In late November, the company announced that Genentech would acquire Jecure Therapeutics, gaining access to Jecure’s portfolio of NLRP3 inhibitors developed to fight
    inflammatory diseases like non-alcoholic steatohepatitis and liver fibrosis.

  • [16] Also in 2005 Roche acquired the Swiss company GlycArt Biotechnology in order to acquire technology to afucosylate antibodies; one of its products in development was obinutuzumab,
    which gained FDA approval in November 2013 for the treatment of chronic lymphocytic leukemia.

  • Products Hoffmann-La Roche develops drugs used for cancer treatment, against virus diseases and for treatment of metabolic diseases.

  • [61] A second gene therapy-related action came in December with the US$1.15 billion acquisition of non-United States rights to an investigational duchenne muscular dystrophy
    gene therapy developed by Sarepta Therapeutics.

  • [62] In November Roche acquired Promedior and its lead treatment – PRM-151 – for the treatment of idiopathic pulmonary fibrosis, for $390 million upfront and another $1 billion
    in milestone payments.

  • [12] Roche has also produced various HIV tests and antiretroviral drugs.

  • [45] In April 2015, Roche acquired CAPP Medical, and its chief development of technology for cancer screening and monitoring via the detection of circulating tumor DNA.

  • Internally, it is organized into five major business areas: Roche Applied Science, Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics and Roche
    Tissue Diagnostics (Ventana).

  • Spark has an already approved treatment for Leber’s congenital amaurosis, Luxturna – priced at US$850,000 per patient.

  • Roche is the fifth largest pharmaceutical company in the world by revenue,[5] and the leading provider of cancer treatments globally.

  • [79] Tamiflu box Drugs produced by Roche include:[needs update][original research?

  • [34] In July 2013, Roche Diagnostics acquired blood diagnostics company Constitution Medical Inc. for $220 million.

  • [54] In February 2018, Roche announced it would acquire Flatiron Health, a business specialising in US cancer data analytics, for $1.9 billion.

  • • Alecensa (alectinib), for ALK-positive non-small cell lung cancer.

  • [44] On 16 January 2015, the company announced that they would acquire Trophos for €470 million ($543 million) in order to increase the company’s neuromuscular disease presence.

  • Roche is the only drug company authorized to manufacture the drug, which was discovered by Gilead Sciences.

  • • Actimmune (interferon gamma), for chronic granulomatous disease, later sold to Connetics Corporation, then InterMune, after that Vidara Therapeutics and finally Horizon
    Pharma as of 2019.

  • [59] In February 2019, the business announced it would acquire gene therapy company, Spark Therapeutics, for US$4.3 billion ($114.50 per share) adding Spark’s gene therapy
    portfolio to its previous acquired assets.

  • [63][64] In March 2020, the Roche Diagnostics division reached a significant milestone with the FDA-approval of its high-volume Sars-CoV-2 diagnostic test, capable of analyzing
    1,400-8,800 samples within 24h on the proprietary cobas 6800/8800 molecular testing system.

  • [11] It manufactures and sells several cancer drugs and is a leader in this field.

  • • Tecentriq (atezolizumab), for non-small cell lung cancer.

  • By the early 1990s, Roche Biomedical became one of the largest clinical laboratory networks in the United States, with 20 major laboratories and US$600 million in sales.

  • Within 2 years of its approval (and that of ritonavir 4 months later) annual deaths from AIDS in the United States fell from over 50,000 to approximately 18,000 [13] On 28
    April 1995 Hoffmann-La Roche sold Roche Biomedical Laboratories, Inc. to National Health Laboratories Holdings Inc. (which then changed its name to Laboratory Corporation of America Holdings).

  • [36] On 7 April 2014, Roche announced its intention to acquire IQuum for up to $450 million,[37] as well as the rights to an experimental drug (ORY-1001) from Spanish company
    Oryzon Genomics for $21 million and up to $500 million in milestone payments.

  • In 1995 the era of highly active anti-retroviral therapy (HAART) was initiated by the United States FDA’s approval of Hoffman LaRoche’s HIV protease inhibitor saquinavir.

  • [72] In September, the company announced it would acquire German biotech group, TIB Molbiol, enhancing its molecular diagnostics operations.

  • [51] In June, the company acquired the diabetes management platform, mySugr GmbH for an undisclosed price.

  • • Rozlytrek (entrectinib), for ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors.

  • Originally, it had been intended to create a more efficient drug at combatting Tuberculosis.

  • [32] In December, Roche announced it would acquire Munich-based Verum Diagnostica GmbH, gaining entry to the fastest-growing field in the coagulation diagnostics market.

  • [66][67] In September the business acquired Ireland-based Inflazome, for €380 million, gaining control of its NLRP3 inflammasome inhibitors.

  • [17][18][19] On 22 January 2008 Roche acquired Ventana Medical Systems for $3.4 billion.

  • • Hivid (zalcitabine), for HIV-1 infection, later discontinued in 2006.

  • F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics.

  • [28] In 2011, the company received the International Society for Pharmaceutical Engineering Facility of the Year Award for Process Innovation for Roche’s “MyDose” Clinical
    Supply project.

  • [9] In 1934, it became the first company to mass-produce synthetic vitamin C, under the brand name Redoxon.

  • • Raptiva (efalizumab), for psoriasis, later withdrawn in 2009 due to the risk of PML.

  • The deal will centre on the Phase II and III spinal muscular atrophy drug olesoxime (TRO19622).

  • [4] All business areas except Roche Applied Science focus on health care applications, targeting either physicians, hospitals and clinics, or consumers.

  • [8] • Type Aktiengesellschaft; Traded as SIX: ROG; ISIN CH0012032048; Industry Pharmaceuticals; Founded 1896, 126 years ago; Founder Fritz Hoffmann-La Roche; Headquarters
    Basel, Switzerland; Key people Christoph Franz (Chairman) André Hoffmann (Vice-Chairman) Severin Schwan (CEO) William N.(Bill) Anderson (CEO, Pharmaceuticals)[1] Thomas Schinecker (CEO, Diagnostics)[2] Levi Garraway CMO[3] ; Products Pharmaceuticals
    and diagnostics (List of products); Revenue 62.80 billion (2021)[4] ; Operating income 18.16 billion (2021)[4] ; Net income 14.94 billion (2021)[4] ; Total assets 92.32 billion (2021)[4] ; Total equity 28.35 billion (2021)[4] ; Number of employees
    100,920 (2021)[4] ; Parent Roche Holding AG; Subsidiaries Genentech, Ventana History Founded in 1896 by Fritz Hoffmann-La Roche, the company was early on known for producing various vitamin preparations and derivatives.

  • [65] In May the company announced it had acquired US-based Stratos Genomics for an undisclosed amount.

 

Works Cited

[‘1. “Executive Committee”. Roche.com. F. Hoffmann-La Roche. Archived from the original on 14 September 2016. Retrieved 26 November 2016.
2. ^ “Roche names new head of $13 billion diagnostics unit”. Reuters. 11 June 2019.
3. ^ “FDA Grants Roche
Breakthrough Therapy Designation on Hemophilia Drug”. BioPharm International. UBM. 19 April 2018. Retrieved 20 April 2018.
4. ^ Jump up to:a b c d e f g “Financial Report 2021” (PDF). Roche Holding. 4 February 2022. Retrieved 5 April 2022.
5. ^
McGlauflin, Paige (15 August 2022). “The world’s 10 biggest pharmaceutical companies raked in over $700 billion in revenue in 2021”. Fortune. Archived from the original on 17 August 2022.
6. ^ “Top 10 Oncology Pharma Companies in the World | Market
Research Blog”. Market Research Reports® Inc. 17 May 2019.
7. ^ “Top 20 pharma companies by oncology sales – Top Pharma List – PMLiVE”. pmlive.com. 16 June 2014.
8. ^ “The Pharmaceutical Industry in Figures – 2008 Edition”. European Federation
of Pharmaceutical Industries and Associations (EFPIA). p. 49. Archived from the original on 16 September 2008. Retrieved 25 August 2008.
9. ^ “Switzerland’s Biggest Family Fortune Has Prospered for 124 Years”. Bloomberg.com. 6 August 2020. Retrieved
16 March 2022.
10. ^ “Chemical firms exploited Nazi links, probe found”.
11. ^ HannahBlake (1 November 2012). “A history of Roche”. pharmaphorum.com. Retrieved 16 March 2022.
12. ^ “Roche Biomedical Laboratories, Inc”. FundingUniverse.com.
13. ^
“HIV Surveillance — United States, 1981—2008”. Retrieved 8 November 2013.
14. ^ Laboratory Corp of America Holdings · 10-Q · For 3/31/95, SECInfo.com, Filed On 5/15/95, SEC File 1-11353, Accession Number 920148-95-11
15. ^ “Roche, Gilead End
Tamiflu Feud”. Red Herring. 16 November 2005.
16. ^ Kher, Unmesh (19 October 2005). “Why Roche Released Tamiflu”. Time. Archived from the original on 22 October 2005. Retrieved 22 May 2008.
17. ^ “Roche – Roche acquires Swiss based GlycArt Biotechnology
to strengthen expertise in therapeutic antibody research”. roche.com. Archived from the original on 5 February 2015. Retrieved 29 April 2015.
18. ^ Presentation: GlycArt Biotechnology AG From Inception to trade sale – and what happened after…
by Dr. Joël Jean-Mairet. Brussels, March 31, 2011
19. ^ Cameron, F; McCormack, PL (January 2014). “Obinutuzumab: first global approval”. Drugs. 74 (1): 147–54. doi:10.1007/s40265-013-0167-3. PMID 24338113. S2CID 40983655.
20. ^ “Roche buys Ventana”.
Archived from the original on 5 June 2014. Retrieved 2 June 2014.
21. ^ Pollack, Andrew (12 March 2009). “Roche buys Memory Pharmaceuticals”. The New York Times. Retrieved 2 June 2014.
22. ^ Pollack, Andrew (12 March 2009). “Roche buys Genentech”.
The New York Times. Retrieved 2 June 2014.
23. ^ Pollack, Andrew (5 February 1990). “Genentech-Roche Deal May Spur Similar Ties”. The New York Times. Retrieved 11 April 2009.
24. ^ Bawden, Tom (13 March 2009). “Roche swallows Genentech in third
large drugs deal”. The Times. London. Archived from the original on 12 June 2011. Retrieved 11 April 2009.
25. ^ Jucca, Lisa; Cage, Sam (26 March 2009). “Roche completes Genentech buy”. Reuters. Retrieved 11 April 2009.
26. ^ Proctor, Owen (17
June 2017). “Ex-Roche campus reinvented as ‘On3’ science center”. northjersey.com. Retrieved 30 August 2022.
27. ^ “Roche buys Medingo”. Archived from the original on 12 January 2014. Retrieved 2 June 2014.
28. ^ “Roche buysBioImagene”. Archived
from the original on 5 June 2014. Retrieved 2 June 2014.
29. ^ “2011 Facility of the Year Category winners”. Retrieved 28 June 2012.
30. ^ “Roche buys PVT”. Archived from the original on 5 June 2014. Retrieved 2 June 2014.
31. ^ “Roche buys
mtm labs”. Archived from the original on 5 June 2014. Retrieved 2 June 2014.
32. ^ “Roche buys Anadys”. Archived from the original on 5 June 2014. Retrieved 2 June 2014.
33. ^ “Roche Acquires Verum Diagnostica GmbH for €11 Million”. BioSpace.
34. ^
“Roche announces closure of Nutley, NJ site”. Archived from the original on 18 May 2013. Retrieved 28 June 2012.
35. ^ “Roche buys Constitution Medical”. Archived from the original on 2 June 2014. Retrieved 2 June 2014.
36. ^ “Genentech Purchases
Arrayit Corporation Technology”. BioSpace.
37. ^ “Roche buys IQuum”. Archived from the original on 2 June 2014. Retrieved 2 June 2014.
38. ^ Copley, Caroline (7 April 2014). “Roche buys experimental drug rights from Oryson”. Reuters. Retrieved
2 June 2014.
39. ^ Mulier, Thomas (2 June 2014). “Roche buys Genia”. Bloomberg. Retrieved 2 June 2014.
40. ^ Michelle Cortez (24 August 2014). “Roche Holding Agrees to Buy InterMune for $8.3 Billion”. Bloomberg L.P.
41. ^ “Roche pays 37% premium
on shares for InterMune in US $8.3bn deal”. San Francisco News.Net. 24 August 2014. Retrieved 24 August 2014.
42. ^ “Roche Bags Santaris Pharma A/S In Deal Worth $450 Million”. BioSpace.
43. ^ “Roche Acquires Big Data Platform Provider”. GEN.
19 December 2014.
44. ^ Jump up to:a b “Roche To Pay Up To $489 Million For Next-Gen Antibody Firm Dutalys”. BioSpace.
45. ^ “Roche to Buy Trophos for Up-to-$543M”. GEN. 16 January 2015.
46. ^ “Roche Grabs CAPP Medical, a “Liquid Biopsy” Startup
Targeting Cancer”. BioSpace.
47. ^ “Roche to Acquire GeneWEAVE for Up-to $425M”. GEN. 13 August 2015.
48. ^ “Roche Acquires Genomic Tools Provider Kapa Biosystems”. GEN. 19 August 2015.
49. ^ “Roche to Acquire Adheron Therapeutics for $105 Upfront
– GEN Genetic Engineering & Biotechnology News – Biotech from Bench to Business – GEN”. GEN. 9 October 2015. Retrieved 23 May 2017.
50. ^ “Roche Acquires Tensha Therapeutics for $115M Upfront – GEN Genetic Engineering & Biotechnology News – Biotech
from Bench to Business – GEN”. GEN. 11 January 2016. Retrieved 23 May 2017.
51. ^ Inc., ForSight VISION4. “ForSight VISION4, Inc. Announces Acquisition by Roche”. PR Newswire.
52. ^ Miller, John (30 June 2017). “Roche buys diabetes app firm in
digital health push”. Reuters.
53. ^ “Roche Scoops Up Bay Area’s Viewics Amid Diagnostic Data Push”. BioSpace.
54. ^ “Roche to buy U.S. cancer drugmaker Ignyta for $1.7 billion”. Reuters.com. Reuters. 22 December 2017.
55. ^ Dye, Jessica (15
February 2018). “Roche pays $1.9bn for Alphabet-backed Flatiron Health”. Financial Times.
56. ^ “Roche to buy Flatiron Health for $1.9 billion to expand cancer care…” Reuters.com. Reuters. 15 February 2018.
57. ^ “Roche pays $2.4 billion for
rest of cancer expert Foundation Medicine”. Reuters.com. Reuters. 19 June 2018.
58. ^ “Roche Acquires Cancer Immunotherapy Developer Tusk Therapeutics”. 28 September 2018.
59. ^ “Roche buys U.S. biotech Jecure in race for liver disease drugs”.
Reuters.com. Reuters. 27 November 2018.
60. ^ “Roche ‘steps up’ for gene therapy with $4.3 billion Spark bet”. Reuters.com. Reuters. 25 February 2019.
61. ^ “Roche says its $4.3 billion offer for Spark is still on track for June completion”.
CNBC. 3 April 2019.
62. ^ Koltrowitz, Silke; Nadeem, Dania (23 December 2019). “Roche dives deeper into gene therapy with $1.15 billion Sarepta licensing deal”. Reuters. Retrieved 24 December 2019.
63. ^ “Roche to Acquire Fibrosis-Focused Promedior
for up to $1.4 Billion”.
64. ^ “Promedior Enters into Definitive Merger Agreement to be Acquired by Roche”.
65. ^ Hale C. (March 2020). “FDA grants Roche coronavirus test emergency green light within 24 hours” FierceBiotech. Retrieved 13 March
2020.
66. ^ “Roche buys U.S. Gene sequencing tech company Stratos Genomics”. Reuters. 22 May 2020.
67. ^ “Roche acquires Stratos Genomics to further develop DNA based sequencing for diagnostic use”.
68. ^ “Roche Dives into NLRP3 Inflammasome
Inhibition with Acquisition of Inflazome”. BioSpace.
69. ^ “Inflazome Announces Acquisition by Roche”. BioSpace.
70. ^ “Roche Bolsters Diagnostics Pipeline with $1.8 Billion Buy of GenMark”.
71. ^ Reuters
72. ^ “Roche signs definitive merger
agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sample”.
73. ^ “Roche Holding to buy TIB Molbiol to enhance molecular diagnostics”. Reuters. 9 September 2021.
74. ^ “Switzerland’s
Biggest Family Fortune Has Prospered for 124 Years”. Bloomberg.com. 6 August 2020.
75. ^ “Nachkomme und Verwaltungsrat Jörg Duschmalé: «Roche war immer da, seit ich ganz klein war»”.
76. ^ “Roche Holding Bilanz, Gewinn und Umsatz | Roche Holding
Geschäftsbericht | 855167”. wallstreet-online.de. Retrieved 5 November 2018.
77. ^ MarketScreener. “ROCHE HOLDING AG : Financial Data Forecasts Estimates and Expectations | ROG | CH0012032048 | MarketScreener”. www.marketscreener.com. Retrieved
3 June 2020.
78. ^ GmbH, finanzen net. “Roche Financials | Markets Insider”. Business Insider. Retrieved 3 June 2020.
79. ^ Miller, John (19 December 2017). “Roche touts Swiss-led R&D unit after years in Genentech’s shadow”. Reuters. Retrieved
19 December 2017.
80. ^ “Roche stops selling acne drug Accutane”. Reuters. 26 June 2009. Retrieved 23 February 2016.
81. ^ Jump up to:a b Mathiason, Nick (25 November 2001). “Blowing the final whistle”. The Observer. Retrieved 30 September 2014.
82. ^
Corporate Crime Reporter. Corporate Crime Reporter. Retrieved 2013-11-24.
83. ^ “Cartel price announcements: The vitamins industry” (PDF). International Journal of Industrial Organization. 26. 2008.
84. ^ Mattes, William B. (2008). “Public Consortium
Efforts in Toxicogenomics”. In Mendrick, Donna L.; Mattes, William B. (eds.). Essential Concepts in Toxicogenomics. Methods in Molecular Biology. Vol. 460. pp. 221–238. doi:10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2. PMID 18449490.
85. ^
“InnoMed PredTox Member Organizations”. Archived from the original on 26 September 2008. Retrieved 2008-08-25.
86. ^ Innovative Medicines Initiative. “IMI Call Topics 2008”. IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. Archived from
the original on 15 October 2009. Retrieved 25 August 2008.
Photo credit: https://www.flickr.com/photos/50826080@N00/8717900362/’]